MCIM
PRTK

Meadow Creek Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Meadow Creek Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,288
Closed -$12K – 1365
2018
Q4 		$12K Buy
+2,288
New +$17.4K ﹤0.01% 1297

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Meadow Creek Investment Management's PRTK Position: Q1 2019 in Review

Meadow Creek Investment Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2019, closing a stake of 2,288 shares — an estimated $12K sold.

Meadow Creek Investment Management first reported a position in PRTK in Q4 2018 and held it in 1 quarter. The position peaked at $12K in Q4 2018. 94 funds tracked by Wall St. Rank hold PRTK as of Q1 2019.

  • Meadow Creek Investment Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Meadow Creek Investment Management sold 2,288 Paratek Pharmaceuticals, Inc. shares in Q1 2019, an estimated $12K.
  • Meadow Creek Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Meadow Creek Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $12K in Q4 2018.
  • 94 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2019.

Based on Meadow Creek Investment Management's 13F filing for Q1 2019, filed 13 May 2019.